Shanghai Celgen Bio-Pharmaceutical

Shanghai Celgen Bio-Pharmaceutical is a China-based biopharmaceutical company specializing in the development and commercialization of biosimilars and innovative biologics for oncology and autoimmune diseases. The company is best known for its flagship product, Qiangke (an etanercept biosimilar), which was approved in China in 2011 for the treatment of ankylosing spondylitis and has since expanded into other autoimmune indications. Beyond its biosimilar portfolio, Shanghai Celgen is advancing a pipeline of novel immunotherapies, including the fully human anti-CTLA-4 monoclonal antibody KD6001, currently in Phase 2 clinical trials for melanoma. The company operates an integrated R&D and GMP-certified biologics manufacturing infrastructure in Shanghai's Zhangjiang Hi-Tech Park. Formerly a strategic partner of Simcere Pharmaceutical, Shanghai Celgen now operates as an independent entity focused on high-growth therapeutic areas in the Chinese market.